Skip to main content

Advertisement

Table 1 Baseline characteristics (demographics, measures of HIV disease and neuropsychiatric symptoms of HIV-only and HIV-TB co-infected (Rifampicin treatment) study participants at initiation of ART

From: Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study

Baseline demographics and measures of HIV disease All participants (n=197) HIV- patients (n=59) HIV-TB patients (n=138) P-value
Proportion of female participants 109 (55.3) 40 (67.8) 69 (50.4) 0.02
Body weight at ART initiation / kg (±SD) 53.6± 10.1 56.5 ± 9.8 51.9± 10.0 0.015
Age / years (±SD) 33.8± 7.2 36.5 ± 6.1 32.7±7.4 0.003
Initial CD4 count (±SD) 97.2± 77.4 123.1± 63.7 86.2± 79.9 0.009
Log10. viral load (±SD) 4.95± 0.71 4.81± 0.73 5.02± 0.70 0.08
Baseline neuropsychiatric Symptoms 61 (31) 14 (23.7 ) 47 (34.1) 0.14
Sleep disorders 36 (18.3) 9(15.2) 27 (19.7) 0.46
Insomnia 21 (10.7) 6(10.2) 15(10.9) 0.88
Vivid dreams 11 (5.6) 4(6.9) 7(5.2) 0.66
Sleep walking 9 (4.6) 0(0.0) 9 (6.67) 0.04
Hallucinations 3(1.5) 1(1.7) 2(1.5) 0.9
   Auditory 3(1.5) 1(1.7) 2(1.5) 0.9
   Visual 0(0.0) 0(0.0) 0(0.0) -
   Tactile 0(0.0) 0(0.0) 0(0.0) -
Cognitive disorder 46 (23.4) 9(15.2) 37 (27.0) 0.07
  1. SD standard deviation.